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Introduction
Within the large family of G protein-coupled receptors 
(GPCR), the adrenergic receptors (ARs) mediate the func-
tional effects of catecholamines, like epinephrine and 
norepinephrine. The AR family includes nine different 
gene products, three β (β
1
, β
2
, β
3
), three α
1
 (α
1a
, α
1b
, and 
α
1d
), and three α
2
 (α
2A
, α
2B
, and α
2C
) receptor subtypes.
The α
1
-AR subtypes are expressed in various organs, 
including brain, heart, blood vessels, liver, kidney, pros-
tate, and spleen, in which they mediate a variety of func-
tional effects such as modulation of neurotransmission, 
vasoconstriction, cardiac inotropy, and chronotropy, 
regulation of metabolism (reviewed in ref. 1). Activation 
of the three α
1
-AR subtypes causes polyphosphoinositide 
hydrolysis catalyzed by phospholipase C (PLC) via per-
tussis toxin-insensitive G proteins in most tissues where 
this effect has been examined (1).
Radioligand binding studies in rat tissues initially 
demonstrated two classes of α
1
-AR binding sites, “A” and 
“B” with high and low affinity for the α
1
-AR  antagonists 
WB4101 and phentolamine, respectively. The first α
1
-AR 
cloned, was unequivocally assigned to the pharma-
cological α
1B
 subtype and hence named α
1b
-AR. The 
pharmacological α
1A
 subtype, today identified as α
1a
-AR, 
was initially cloned from a bovine brain library and 
inappropriately named α
1C
-AR or α
1A/C
-AR. Finally, the 
cloned α
1d
-AR (initially named α
1A
-AR or α
1A/D
-AR) was a 
novel receptor subtype not clearly identified by previous 
 pharmacological studies (reviewed in ref. 2,3).
Studies aiming to assess the specific functional 
responses mediated by distinct α
1
-AR subtypes have 
been hampered by the fact that the subtype-selective 
drugs are only moderately selective. Recently, studies 
on genetically modified mice lacking or overexpressing 
one or more α
1
-AR subtypes have provided some impor-
tant insight into the functional roles played by distinct 
receptors. However, our understanding on the functional 
implications of α
1
-AR heterogeneity in physiological 
 systems is still quite limited.
Extensive mutational analysis performed by our group 
and other investigators helped to identify the structural 
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determinants of the α
1
-AR subtypes involved in each of 
the three main “classical” functional properties of GPCRs: 
(i) ligand-binding; (ii) receptor activation and coupling to 
G protein; and (iii) desensitization. These findings have 
been reviewed elsewhere (4,5). Beyond these “classical” 
features, a number of novel functional paradigms have 
been recently described for GPCRs including receptor 
constitutive activity (6), oligomerization (7) and interac-
tion with a variety of signaling proteins (8). These func-
tional features imply a growing complexity of signaling 
and regulation of the α
1
-AR subtypes which might repre-
sent the mechanistic basis of their functional specificity 
in various tissues.
The aim of this review is to summarize our current 
knowledge on some recently identified functional para-
digms and signaling networks that might help to elucidate 
the functional diversity of the α
1
-AR subtypes in various 
organs.
Constitutive activity of the α1-AR subtypes
For both the α
1a
 and α
1b
-AR mutation-induced and spon-
taneous constitutive activity have been reported (9,10). 
Interestingly, most of the known α-blockers behave as 
inverse agonists both at the wild type and constitutively 
actve mutants of the two receptors (10). Studies on 
constitutively activating mutations of the α
1b
-AR pro-
vided important insight into the potential molecular 
mechanisms of GPCR activation (11). In particular, they 
highlighted the highly conserved E/DRY sequence at the 
cytoslic end of helix 3 as an important switch of receptor 
activation.
Interestingly, activating mutations which perturb the 
helix 3/helix 6 packing of the receptor have been found 
in both the α
1a
 and α
1b
-AR subtypes suggesting common 
mechanisms of receptor activation (12). These include: 
(i) mutations of A293(6.34) and of A271(6.34) in the cytosolic 
extension of helix 6 in the α
1b
-AR and α
1a
-AR, respec-
tively (9,10); (ii) mutations of D142(3.49) and D123(3.49) of 
the E/DRY motif in the α
1b
-AR and α
1a
-AR, respectively 
(10,11).
However, some differences in the activation prop-
erties can be observed between the α
1a
 and α
1b
-AR in 
recombinant systems measuring the inositol phosphate 
response. The agonist-independent activity of both the 
wild type α
1b
-AR and its constitutively active mutants was 
significantly higher than that of the wild type α
1a
-AR or 
its mutant. In contrast, the epinephrine-induced inositol 
phosphate accumulation above basal at the α
1a
-AR was 
significantly higher than that at the α
1b
-AR or its consti-
tutively active mutants expressed at comparable levels 
(10,13). This suggests that in recombinant systems the 
agonist-occupied α
1a
-AR has greater efficacy in activat-
ing PLC than the α
1b
-AR whereas its spontaneous or 
mutation-induced isomerization toward the active states 
is lower. Only one study reported the opposite showing 
that in rat neonatal cardiomyocytes a different constitu-
tively active mutant of the α
1a
-AR displayed higher basal 
activity than the analogous mutant of the α
1b
-AR (14). This 
finding is intriguing and should be further explored.
The properties of the α
1d
-AR subtype have been 
investigated very little because its expression as well 
as the agonist-induced inositol phosphate response 
mediated by this receptor were often found to be much 
smaller than those of the other two subtypes (15,16). 
Constitutively activating mutations of the α
1d
-AR have 
not been reported so far. However, an interesting study 
reported that the α
1d
-AR expressed in rat fibroblasts is 
constitutively active and internalized (17). In fact, the 
basal activity of the α
1d
-AR was 2-fold greater than that 
of the α
1b
-AR and was increased following the treat-
ment with the inverse agonist prazosin which caused its 
redistribution from the intracellular compartments to 
the plasma membrane. The constitutive activity of the 
α
1d
-AR was also observed in physiological systems like 
in aorta and mesenteric arteries where it could inhib-
ited by inverse agonists (18). For the α
1a
 or α
1b
-AR con-
stitutive activity in physiological systems has not been 
investigated.
Altogether, these findings indicate that there might be 
important differences in the constitutive activity of the 
α
1
-AR subtypes which could have consequences in their 
signaling and regulatory properties in vivo. Such differ-
ences should be further explored and the elucidation 
of their physiological implications might represent an 
important area of investigation.
Oligomerization of the α1-AR subtypes
Findings in the last decade challenged the widely 
held view of GPCRs functioning as monomeric units. 
Co-immunoprecipitation of differentially tagged GPCRs 
or functional complementation of pairs of co-expressed 
inactive receptor mutants provided strong evidence 
that GPCR oligomers do exist. The widespread use of 
biophysical techniques such as fluorescence resonance 
energy transfer (FRET) or bioluminescence resonance 
energy transfer (BRET) between GPCRs carrying the 
appropriate pair of fluorescent/bioluminescent labels 
suggested oligomerization of a variety of GPCRs. Each 
technique employed has its own shortcomings: whereas 
co-immunoprecipitation cannot rule out indirect inter-
action, energy transfer techniques can only certify that 
the two partners are in close proximity, not necessar-
ily in immediate contact. However, convergent results 
obtained through independent methods eventually led 
to the widespread acknowledgment of the existence of 
GPCR oligomers (7).
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Both homo- and hetero-oligomerization have been 
demonstrated for the three α
1
-AR subtypes in recom-
binant systems (Table 1) (15,16,19). FRET measurements 
as well as co-immunoprecipitation experiments provided 
evidence that both the α1a and α1b-AR can form homo-
oligomers (19). Oligomerization of the α
1b
-AR did not 
require the integrity of its C-tail, of two glycophorin motifs 
or of the N-linked glycosylation sites at its N-terminus. 
Constitutively active or non-functional α
1b
-AR mutants 
displayed the same propensity to oligomerize as the wild-
type receptor, indicating that the activation state of the 
receptor is irrelevant for this process. Receptor oligomeri-
zation was not influenced by the agonist epinephrine or 
by the inverse agonist prazosin. Thus, whether homo-
oligomerization of the α
1a
 or α
1b
-AR has any functional 
relevance is unknown.
Hetero-oligomers were observed between the α
1a
 and 
the α
1b
-AR subtypes, but not between the α
1b
-AR and 
other GPCRs. Interestingly, hetero-oligomerization was 
found to have an impact on receptor endocytosis (19). 
Whereas the α
1b
-AR undergoes agonist-induced inter-
nalization, the α
1a
-AR does not. However, when the two 
AR subtypes were co-expressed forming heterodimers, 
the endocytosis of each monomer could be triggered 
by stimulation of the other. Colocalization of the two 
monomers could be seen in endocytic vesicles suggesting 
that the α
1a
/α
1b
 dimers remained stable throughout the 
endocytosis process.
An important effect of hetero-oligomerization has been 
reported for the α
1d
-AR subytpe. In fact, co-expression of 
the α
1d
AR with the α
1b
AR (15) or the β
2
AR (19) was able 
to rescue surface expression of the α
1d
-AR, the majority 
of which is intracellular when expressed alone in various 
cell lines. Interestingly, the interaction with the α
1b
-AR 
modified the pharmacological profile of the α
1d
-AR which 
looses its affinity for its selective ligand BMY7378 when it 
is co-expressed with the α
1b
-AR. The α
1b
/α
1d
 dimer behaves 
as a single functional entity with increased response to 
norepinephrine relative to either monomer alone. The 
α
1d
-AR receptor was long supposed to be little expressed 
in the heart, as its selective ligand BMY7378 could detect 
only minimal levels of the receptor. However, these find-
ings should be considered in a new light, given that the 
α
1b
 and α
1d
-AR subtypes co-exist in various tissues and the 
pharmacological profile of the α
1d
-AR might be different 
than expected because of oligomerization.
Oligomerization of α
1
-AR subytpes in physiological 
systems has not been explored so far for lack of appro-
priate experimental tools. Therefore, the functional rel-
evance of α
1
-AR oligomerization in vivo remains elusive. 
However, oligomerization might represent an additional 
mechanism regulating the physiological responses medi-
ated by the α
1
-AR subytpes which are often co-expressed 
in the same cells. Further exploring the functional cor-
relates of receptor oligomerization and assessing if it 
occurs in physiological systems might provide interesting 
information about cross-talk effects at the level of α
1
-AR 
signaling or regulation.
Signaling pathways of the α1-AR subytpes
It has become increasingly evident that the variety of 
functional effects mediated by the α
1
-ARs in different 
organs must imply the activation of multiple signaling 
pathways beyond activation of PLC via Gq/11. Therefore, 
several studies have attempted to investigate whether 
each α
1
-AR subtype may activate distinct signaling path-
ways, but our knowledge on this issue is still limited.
It has been reported that stimulation of the α
1b
 and 
α
1d
-AR can result in the activation of phospholipase A2 in 
COS-1 cells (20); the α
1a
-AR was not explored. In NIH3T3 
cells, the activation of the α
1a
 and α
1b
-AR, but not that of 
the α
1d
, resulted in the stimulation of p21-ras, PI3-kinase 
and mitogen-activated protein kinase (MAPK) (21). 
However, the steps leading to the activation of these path-
ways seem to differ between the two receptor subtypes.
In hepatocyte derived cells, stimulation of the α
1b
-AR 
subtype inhibits interleukin 6 signaling by a MAPK 
mechanism (22). An interesting microarray study indi-
cated that the α
1
-AR subtypes expressed in Rat fibroblasts 
have a differential effect on cell cycle genes with the α
1b
 
mediating cell-cycle progression, and the α
1a
 and α
1d
-AR 
mediating G1-S cell cycle arrest (23).
Most of the work investigating α
1
-AR signaling has 
been performed in cardiomyocytes. In fact, hearts of 
most species express both α
1a
 and α
1b
-AR at protein 
level whereas the expression of α
1d
-AR is very low. The 
α
1a
-AR predominates in humans, whereas the α
1b
-AR in 
rodents. Some seminal studies (24,25) demonstrated that 
stimulation of the α
1
-ARs in cardiomyocytes induces a 
hypertrophic response accompanied by the activation 
of early genes (c-fos, c-jun, egr-1) upreagulation of con-
tractile proteins (myosin light chain-2) and reactivation 
of embryonic genes (atrial natriuretic factor (ANF), 
β-myosin heavy chain, skeletal α-actin).
Various studies provided clear evidence for the 
 involvement of both the PLC–MAPK pathway (26) and 
Table 1. Oligomerization of the α
1
-adrenergic receptor subtypes.
Receptors Trafficking Pharmacology Signaling Ref.
α
1a
/α
1b
Co-endocytosis No change — 19
α
1b
/α
1d
↑ α
1d
 Surface 
expression
↓ α
1d
 Affinity for 
selective ligands
↑ Signaling 15
α
1d
/β
2
↑ α
1d
 Surface 
expression 
co-endocytosis
— — 16
Homo-
oligomers 
α
1a
, α
1b
, α
1d
— — — 15,19
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Rho-signaling (27) in the α
1
-AR-induced hypertrophic 
response in cardiomyocytes. A recent study supports 
these earlier findings suggesting that α
1
-AR-induced 
cardiac hypertrophy is mediated by three parallel path-
ways: G12/13-Rho-JNK, Gq-JNK (Rho-independent) 
and Gβγ (JNK independent) (28). Recent findings have 
demonstrated that the α
1
-ARs endogenously expressed 
in rat neonatal cardiomocytes promote RhoA-activation 
via a mechanism that requires G12 and the Rho-guanine 
nucleotide exchange factor AKAP-Lbc and this pathway 
mediates hypertrophy (29).
The respective role in stimulating cardiac hypertro-
phy of the two α
1
-AR subtypes expressed in heart, the 
α
1a
 and α
1b
-AR, does not emerge clearly from the in 
vitro studies published so far probably because of the 
limited selectivity of the pharmacological tools avail-
able. In one study on rat neonatal cardiomyocytes, a 
constitutively active form of the α
1a
-AR activated gene 
expression of the ANF, whereas the analogous consti-
tutively active mutant of the α
1b
-AR stimulated gene 
expression of c-fos, but not of ANF (14). However, 
these findings are intriguing considering that other 
studies reported the opposite and that overexpression 
of the α
1b
-AR in transgenic mice resulted in a marked 
increase in ANF (see below). In the future, it would 
be  interesting to carry on a systematic investigation 
of different signaling pathways comparing the α
1
-AR 
subtypes expressed in the same cellular systems and to 
correlate these findings with the growing information 
provided by in vivo studies on genetically modified 
mice (see below).
Regulatory mechanisms and βarrestin 
interaction at the α1-AR subytpes
The α
1
-AR subtypes display quite divergent regulatory 
properties. In fact, the α
1b
-AR in recombinant systems 
undergoes rapid phospohorylation, desensitization 
and endocytosis upon exposure to the agonist (30–32). 
Desensitization involves phosphorylation of residues in 
the C-tail of the receptor mediated by G protein-coupled 
receptor kinases (GRKs) (31). The endocytosis of the 
α
1b
-AR occurs via clathrin-coated vesicles and seems to 
involve βarrestins (32).
In contrast, the α
1a
-AR expressed in rat-1 fibroblasts 
is poorly phosphorylated and desensitized compared to 
the α
1b
-AR (33). In addition, it undergoes very modest 
agonist-induced endocytosis (32).
Fewer studies have investigated the desensitiza-
tion of the α
1d
-AR probably because of its poor expres-
sion in recombinant systems. It has been reported that 
 noradrenaline and direct activation of protein kinase C 
induce phosphorylation of the α
1d
-AR and this corre-
lates with desensitization of the receptor (34). However, 
desensitization of the α
1d
-AR was not compared with that 
of the other two subtypes in this study.
Overall, the impact of α
1
-AR desensitization in physi-
ological systems where the receptors are endogenously 
expressed has been poorly investigated, as it is the case 
for most GPCRs. Therefore, what is the impact of different 
regulatory properties of the α
1
-AR subtypes on complex 
functions like vasoconstriction, metabolic response, and 
others, is unknown.
Interestingly, the different regulatory features of the 
α
1a
 and α
1b
-AR seem to correlate with their pattern of 
interaction with βarrestins. In fact, the results from both 
co-immunoprecipitation experiments and βarrestin 
translocation assays indicated that the agonist-induced 
interaction of the α
1a
-AR with βarrestin was much 
weaker than that of the α
1b
-AR (32). The interaction of 
βarrestin with the α
1d
-AR has not been directly explored 
so far.
These differences in receptor/βarrestin interaction 
might have broader implications in α
1
-AR mediated 
signaling because of the well established role played by 
βarrestins in coordinating a variety of signaling networks 
(35). In particular, it is well established that βarrestins 
are scaffolds for components of the MAPK cascade thus 
mediating MAPK activation induced by various GPCRs. 
Investigation of βarrestin-mediated signaling at the α
1
-AR 
subtypes is an interesting area of investigation which 
has been poorly explored so far and might represent 
one of the mechanisms contributing to the variety of the 
receptor-mediated-responses.
Proteins interacting with different α1-AR 
subtypes
One of the most recent paradigms is that GPCRs can bind 
a variety of proteins and this can promote multiple sig-
naling events which results in growing complexity of the 
receptor-mediated cellular effects (8)
A number of approaches have been followed to iden-
tify novel proteins interacting with the α
1
-ARs, including 
yeast two-hybrid screen using cytosolic portions of the 
receptors as bait, pull-down or in vitro overlay assays 
using purified proteins, co-immunoprecipitation of 
receptor-protein complexes from recombinant or native 
cells, FRET or BRET technology in cells. These stud-
ies resulted in the identification of a variety of proteins 
interacting with the α
1
-AR subtypes, several of them in a 
receptor subtype selective pattern (Table 2).
The α
1a
-AR subtype contains a PDZ binding sequence 
G-E-E-V at its C-terminus that can be expected to give rise 
to PDZ-domain mediated interactions. An early report, at 
the issue of a yeast two-hybrid screen, identified the type 
III PDZ domain of nNOS (neuronal nitric oxide synthase) 
as a potential α
1a
-AR interacting protein (36) However, 
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co-immunoprecipitation studies, while confirming this 
interaction, failed to highlight selectivity for the α
1a
-AR 
subtype since all three α
1
-AR subtypes could be co-im-
munoprecipitated with nNOS and this even when they 
were lacking their C-terminus. This interaction appeared 
to be without apparent physiological implications in spite 
of the known role of NO in the regulation of blood pres-
sure and of nNOS as local metabolic inhibitor of α
1
-AR 
-mediated vasoconstriction.
Another study reported that the CUB5 domain of 
mammalian tolloid (mTLD), a zinc-finger matrix metal-
loprotease of the astacin family, interacted with α
1a
-AR 
C-tail in a yeast two hybrid screen (37). Overexpression 
of mTLD reduced the number of cell surface receptors 
without affecting total receptor level or affinity when 
transiently expressed in HEK293 cells. No mechanism 
was proposed to account for the observed phenomena.
Interesting prospects were opened by the report of the 
direct interaction between RGS2 (regulator of G protein 
signaling 2) and the third intracellular loop of the α
1a
-AR 
(38). RGS proteins are well characterized inhibitors of het-
erotrimeric G protein function, acting as GAPs (GTPase 
activating proteins) to increase the rate of GTP hydrolysis 
at Gα subunits and thus terminate signaling. More than 
30 RGS proteins have been identified so far, but many RGS 
proteins can non-selectively bind to and inhibit Gαi/o and 
Gαq11 in reconstituted systems, suggesting that other fac-
tors may regulate their specificity for a particular signaling 
pathway. RGS2 was found to interact with the α
1a
-AR third 
intracellular loop confirming what previously shown for 
other Gq-coupled receptors, namely the cholinergic mus-
carinic M1, M3, and M5 receptors (39) and it inhibited 
agonist-induced inositol phosphate responses without 
affecting ligand binding.
Two main interacting partners were pulled out of a 
yeast two-hybrid screen for the α
1b
-AR: the µ2 (or AP50) 
subunit of the clathrin adaptor complex AP2 (40) and 
ezrin, a member of the ezrin-radixin-moesin (ERM) 
protein family (41). The AP2 complex is part of the 
endocytic machinery mediating clathrin-dependent 
endocytosis of membrane proteins and it is recruited 
to agonist-activated GPCRs through the intermission 
of βarrestins. Binding of AP50 relied on a basic stretch 
of eight arginines in the proximal C-tail of the receptor. 
Direct association of the α
1b
-AR to AP50 contributed to 
the agonist-induced internalization of the receptor as 
demonstrated by the fact that a receptor mutant lacking 
the AP50 binding motif was delayed in internalization. 
The presence of the eight arginine motif in the C-tail of 
a GPCR is not common, which rules out the hypothesis 
that direct AP50 interaction is a common mechanism 
for clathrin-mediated endocytosis. Interestingly, this 
feature is shared by the α
1d
-AR, which contains a stretch 
of seven positive charges in its C-tail, but no studies were 
 undertaken using this receptor subytpe.
In addition to AP50, the same yeast two-hybrid 
screen identified ezrin as a potentially direct bind-
ing partner of the α
1b
-AR (41). Ezrin belongs to the 
ERM family of proteins, primarily described as link-
ers between membrane proteins and cortical actin. 
Ezrin interactions with polytopic membrane proteins 
generally occur through the adaptor proteins EBP50 
(NHERF1) and E3KARP (NHERF2). So far, a role for 
the ERM proteins in GPCR trafficking was inferred 
from the finding that NHERF1 binding to some GPCRs 
promoted their recycling, depending on its bind-
ing to ERM proteins. The α
1b
-AR is the first GPCR for 
which a direct interaction with ezrin has been found. 
Disruption of this interaction by overexpression of a 
dominant negative mutant of ezrin inhibited receptor 
reycling after internalization, as did actin depolymeri-
zation. However, ezrin was also shown to be involved 
in the remodelling of the actin cytoskeleton, in the 
modulation of Rho-signaling (by binding to Rho-GTP 
dissociation inhibitor and thourgh direct association 
to several Rho-GTP/GDP exchange factors) as well as 
in anchoring of protein kinase A. Therefore, it would 
be interesting to test whether ezrin is also involved in 
ρ-signaling  mediated by the α
1b
-AR.
Another protein, the receptor for globular “Heads” 
of c1q (gC1qR), was reported to interact with the same 
arginine-rich sequence in the α
1b
 and the α
1d
-AR (42). 
gC1qR is a glycoprotein mainly displaying intracellular 
localization, but also present on the surface of macro-
phages and T cells through anchoring to β-integrin, where 
it is part of a complement receptor. No functional relevance 
was demonstrated for its interaction with the α
1
-ARs.
An interesting protein found to interact with the α
1b
-AR 
is spinophilin which interacts with other GPCRs, includ-
ing the α
2
-AR, as well as with the N-terminal domain of 
RGS proteins (RGS1, 2, 4, and 16) which participates in 
GPCR recognition (43). Thus spinophilin might represent 
an interesting functional bridge between RGS and α
1
AR 
subtypes that don’t bind RGS, like the α
1b
AR. In fact, it has 
been found that spinophilin increases the RGS2-induced 
Table 2. Proteins interacting with the α
1
-adrenergic receptor 
subtypes.
Receptor Partner Binding site Functional role Ref.
α
1a
 α
1b
 α
1d
nNOS Unknown Unknown 36
α
1a
Tolloid C-tail ↓ Surface expression 37
α
1a
RGS2 i3 loop(K219-
S220-R238)
↓ Gq signaling 38
α
1b
AP50 C-tail (8 Arg) ↑ Endocytosis 40
α
1b
Ezrin C-tail (8 Arg) ↑ Recycling 41
α
1b
Spinophilin i3 loop ↓ Ca2+ signaling 
induced by RGS2
43
α
1d
Syntrophins C-term (ETDI) Stabilization of 
 receptor at cell surface
44
α
1b
 α
1d
gC1qR C-tail (Arg) Unknown 42
The α1-adrenergic receptors  415
inhibition of the α
1b
-AR calcium response. These data 
offer a glimpse into a potentially more general regulatory 
mechanisms of GPCR function by spinophilin.
The α
1d
-AR was for a long time a “poor relative” to 
the other α
1
AR subtypes, the α
1A
 and α
1B
 because poorly 
expressed at the cell surface in heterologous systems, 
probably because of its long N-terminus. This peculiarity 
hampered the investigation of its potential interactions 
with other proteins. Apart from the above mentioned 
interaction with gC1qR, whose functional implications 
are unknown (42), another interacting partner of the 
α
1d
-AR was α-syntrophin (44). α-syntrophin, a protein 
containing one PDZ domain and two PH (pleckstrin 
homology) domains, specifically recognized the C-tail of 
the α
1d
-AR, but not that of the α
1a
 or α
1b
, in the yeast two-
hybrid assay. The PDZ domains of syntrophin isoforms α, 
β1, and β2, but not γ1 or γ2, could interact with the α
1d
AR 
C-tail. The α
1d
-AR possesses the C-terminal sequence 
E-T-D-I, whose mutation impaired syntrophin binding 
to the receptor and markedly decreased norepinephrine-
induced inositol phosphate accumulation. This mutation 
also dramatically decreased receptor expression levels. 
Taken altogether these results suggested that syntrophins 
act to maintain the stability of the α
1d
-AR through a 
 PDZ-mediated interaction.
Altogether these findings indicate a rather complex 
and heterogeneous pattern of receptor/protein interac-
tions whose physiological implications are far from being 
fully elucidated. The direct interaction of α
1
AR subtypes 
with selected partners identified in recombinant systems 
might result in new mechanisms of receptor signaling and 
regulation. Since these mechanisms might be specific for 
distinct receptors or cell types, the study of these interac-
tions is an interesting approach to better understand the 
functional specificity of the receptors. However, this would 
require a systematic proteomic approach in different tis-
sues expressing the α
1
AR subtypes as well as good experi-
mental tools to investigate its functional implications.
Insights from genetically modified mice
Recently, mouse lines carrying genetic modifications of the 
α
1
-AR subtypes have provided interesting information on 
the in vivo functions of the receptors giving some insight 
into the specificity of their role. The α
1b
-AR knock out (KO) 
mouse was the first model to be created (45) and it was 
characterized for a number of functional parameters. 
The α
1b
KO mice displayed: (i) decreased blood pressure 
response to phenylephrine with normal resting pressure 
(45); (ii) hyperinsulinemia, insulin resistance and high 
fat diet-induced obesity (46); and (iii) behavioral changes 
including blunted locomotor response to drugs of abuse 
and markedly decreased sensitivity to morphine and 
cocaine (47). Other mice carrying genetic modifications 
of the α
1
-AR subtypes have been mainly characterized for 
their cardiovascular phenotype (Table 3) thus allowing to 
build a more comprehensive picture of the functional role 
of each receptor in the cardiovascular system.
Both the α
1a
 and α
1d
-AR KO mice displayed decreased 
resting blood pressure as well as phenylephrine stimu-
lated pressure response (48,49). The fact that the acute 
response to phenylephrine is decreased in all three KO 
mice indicates that the α
1a
, α
1b
 and α
1d
-AR all  contribute to 
the regulation of the vascular tone. However, the contribu-
tion of the α
1a
 and α
1d
-AR subtypes is prominent because 
deletion of either one of the two receptors leads also to 
decreased resting blood pressure. This can be explained 
by the fact that the α
1a
-AR prevails in distributing arteries 
(mesenteric, renal) (48) and the α
1d
-AR in large conduct-
ing arteries (aorta and carotid) (49), whereas the expres-
sion of the α
1b
-AR is minor in all arteries.
Studies on genetically modified mice have also pro-
vided interesting insight into the role of the α
1
-AR in car-
diac function and hypertrophy. As mentioned above, the 
α
1a
 and α
1b
-AR subtypes are both expressed in cardiomyo-
cytes with the α
1a
 predominating in humans and the α
1b
 in 
rodents. Transgenic mice overexpressing a constitutively 
active α
1b
-AR mutant specifically in the heart display car-
diac hypertrophy without any change in blood pressure 
(50). This supports previous evidence that stimulation of 
α
1
-ARs in cardiomyocytes in vitro leads to a hypertrophic 
response (24). This finding is also consistent with the role 
played by the Gq/PLC pathway in heart as demonstrated 
by the fact that transgenic mice overexpressing a constitu-
tively active Gαq develop cardiac hypertrophy (51).
Interestingly, another transgenic mouse overxepress-
ing a different constitutively active α
1b
-AR mutant, under 
the control of the receptor own promoter, displayed 
a more complex phenotype characterized by cardiac 
hypertrophy as well as autonomic failure (52). This con-
firms a direct role of the α
1b
-AR in cardiac hypertrophy, 
but indicates that broader effects occur when the  receptor 
is generally overexpressed.
Mice overexpressing constitutively active mutant of 
the α
1a
-AR subtype have not been generated. However, 
the role of the α
1a
-AR in heart growth in vivo has been 
demonstrated by studies on double KO mice carrying 
deletions of both the α
1a
 and α
1b
-AR (53) which displayed 
several abnormalities including: (i) reduced growth of 
the heart after birth; (ii) reduced cardiac output; and 
(iii) increased mortality after pressure overload. These 
findings demonstrate that both the α
1a
 and α
1b
-AR play 
an important role in heart growth after birth and their 
integrity is required to maintain correct heart function.
These changes were, however, sex specific since 
they were observed in males, but not in females. This 
might be explained by the fact that females have a lower 
sympathetic tone and the growth of their hearts is less 
 dependent on the α
1
-ARs.
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Cardiac hypertrophy was not observed in transgenic 
mice with cardiac-specific overexpression of the wild 
type α
1a
 or α
1b
-AR subtype (54,55) despite the fact that 
they displayed increased expression of ANF. This is unlike 
the phenotype of mice overexpressing the constitutively 
active α
1b
-AR mutant (50). This difference might be due to 
the fact that the signaling of a constitutively active mutant 
is somehow different or has greater efficacy than that of 
the wild-type receptor.
However, transgenic mice overexpressing either the 
α
1a
 or α
1b
-AR subtype in the heart provided a number of 
novel findings on the functional role of these receptors in 
heart. In fact, in the heart of the α
1b
-AR transgenic mice 
left ventricular contraction in response to β-agonists was 
depressed (55). Interestingly, it was found that dampen-
ing of β-AR signaling through adenylate cyclase was due 
to activation of a pertussis-sensitive inhibitory G protein. 
This clearly suggests that when overexpressed α
1
-ARs can 
couple to inhibitory G proteins.
In conclusion, as summarized in Figure 1, studies 
on mice carrying genetic modifications of the α
1
-AR 
genes have provided evidence that: (a) all three α
1
-AR 
α1a, α1b,
α1d>α1b
α1a>α1b
heart growth/hypertrophy
inotropy
vasoconstriction of
conducting arteries
(aorta, carotid)
vasoconstriction of
resistance arteries
(renal, mesenteric)
Figure 1. The α
1
-adrenergic receptor subtypes in the cardiovascu-
lar system. This figure summarizes the main roles played by distinct 
α
1
-AR subtypes in the cardiovascular system highlighted by studies on 
genetically modified mice.
Table 3. Cardiovascular phenotype of mice carrying genetic modifications of different α
1
-adrenergic receptor subtypes.
Receptor Genetic modification Phenotype Ref.
α
1b
Gene deletion ↓ Resting blood pressure 
↓ Blood pressure response to phenylephrine
48
α
1a
Overexpression/heart-specific promoter ↑ Contractile response 
↑ Survival 
↑ ANF mRNA  
No hypertrophy 
↑ Post-ischemic protection
54
α
1b
Gene deletion Normal resting blood  pressure 
↓ Blood pressure response to phenylephrine 
↓ Vasoconstriction
45
α
1b
Overexpression/heart-specific promoter ↑ Phospholipase C activity 
↑ ANF mRNA  
No hypertrophy  
↓ Contractile and heart rate response to β-AR
55
CAM α
1b
Overexpression/heart-specific promoter ↑ Phospholipase C activity  
↑ Hypertrophy  
↑ ANF mRNA  
Normal blood pressure
50
CAM α
1b
Overexpression/receptor promoter ↓ Contractile response to β-AR 
Autonomic failure  
↑ Hypertrophy
52
α
1a
 α
1b
Double gene deletion In malesNormal resting blood pressure  
↓ Cardiac growth after birth  
↓ Heart rate, ↓ cardiac output  
↓ Basal ERK activity  
↑ Mortality to pressure overload  
Contraction abnormalities
53
α
1d
Gene deletion ↓ Resting blood pressure  
↓ Blood pressure response to phenylephrine  
↓ Vasoconstriction
49
α
1d
α
1b
Double gene deletion ↓ Resting blood pressure 
↓↓ Blood pressure response to phenylephrine 
↓↓ Vasoconstriction
57
The α1-adrenergic receptors  417
subtypes contribute to the regulation of blood  pressure 
with a prominent role for the α
1a
 and α
1d
; (b) both the 
α
1a
 and α
1b
-AR play a role in cardiac pathological hyper-
trophy (independent from pressure overload) or physi-
ological hypertrophy associated with postnatal growth; 
and (c) the α
1
-ARs maintain normal heart function as 
demonstrated by the fact that the double deletion of 
the α
1a
 and α
1b
-AR results in some features of failing 
heart.
Other interesting features of the α
1
-AR subtypes have 
emerged from studies on the genetically modified mice 
including their effects on heart contractile function, 
cardiac rhythm and protection from ischemic injury 
(56). Additional studies are required to gain a deeper 
 understanding of these complex effects.
Conclusions and perspectives
In the past years, we have gained significant information 
of some molecular properties and functional implica-
tions of the α
1
-AR subtypes both from in vitro and in vivo 
studies.
Several studies focused on individual receptor sub-
types whereas only few others attempted to compare the 
behavior of different receptors in similar experimental 
conditions. This latter approach should be implemented 
in future studies, both in vitro and in vivo, to better assess 
differences and similarities among the three α
1
-AR 
subtypes.
The elucidation of receptor-mediated signaling 
events in time and space will depend on a much deeper 
understanding of the interactions among receptors and 
signaling molecules which has recently emerged as an 
important paradigm in the GPCR field. Beyond receptor 
oligomerization (Table 1), a number of novel proteins 
have been found to interact with the α
1
-AR subtypes 
(Table 2), but for most of these interactions the functional 
implications are elusive. The vast majority of studies on 
α
1
-AR subtypes have been performed in recombinant 
systems. A big challenge in the future will be to explore 
the functional implications of a variety of interactions in 
different tissues and physiological conditions. The α
1
-AR 
subtypes are important regulators of several physiologi-
cal parameters as highlighted by studies in genetically 
modified mice (Table 3), and further investigation on this 
receptor system might have new interesting implications 
in pharmacology and drug development.
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